arrow-left-endarrow-right-end

News & Updates

The Latest on Internet Pharmacies, Supplements, Designer Drugs,
and Other High-Risk Merchants

Filter By:

January is the Season for Risky Weight Loss Products

Losing weight is typically the number one New Year’s resolution — and cybercriminals know it. According to research firm Research and Markets, the largest diet surge is in January as people exit the holiday season and set New Year’s resolutions about their health. For this reason, it’s important for payment service providers and e-commerce platforms to watch out for those selling potentially violative products.

Continue Reading ›

FTC Steps Up Actions Against Deceptive Marketers Online

Last month, the Federal Trade Commission (FTC) announced actions or settlements against multiple businesses it alleges engaged in various forms of deceptive and misleading online marketing. The variety of businesses — from supplement merchants to student loan consolidators — demonstrates the broad use of deceptive practices and how they continue to flourish online. It’s a…

Continue Reading ›

LegitScript Study Shows Widespread Problems and Potential Dangers in Online CBD Market

Over the past six months, LegitScript’s analysts and policy experts have been conducting a research project to better understand the online CBD landscape. We’ve looked at the state of compliance, the safety and accuracy of products, and issues around payment processing. What we found in this landmark report is nothing short of disturbing for both…

Continue Reading ›

“Alzheimer’s” on Track to Win LegitScript’s Infamous Yellow Flag Award for 2019

“Alzheimer’s” and related disease terms are on track to be this year’s top impermissible supplement marketing claim, which would earn it the LegitScript Yellow Flag Award for 2019. With four months still left in the year, will “Alzheimer’s” beat last year’s top impermissible claim — “inflammation” — or 2017’s winner, “cancer”? Only time and shady…

Continue Reading ›

The Top Marketing Claims CBD Merchants and Manufacturers Should Avoid

One of the aspects of cannabidiol (CBD) sales that can attract regulatory scrutiny is the way in which merchants market their CBD products. In the past five years, the FDA has sent many warning letters to manufacturers and merchants of CBD products for claims that their products can prevent, cure, mitigate, or treat diseases. No…

Continue Reading ›

[Webinar]
[Webinar]